Resolvin D1 (RvD1; Item No. 10012554) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (Item No. 90310) by 15- and 5-lipoxygenase (Item No. 60402).¹ It reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with an EC₅₀ value of ~30 nM.² RvD1 methyl ester is a methyl ester version of the free acid that may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.

≥97%